Shares of warehouse automation leader Symbotic tumbled sharply ahead of its Q2 2026 earnings report, as investors grapple with insider selling activity and questions over its premium valuation. The upcoming guidance on revenue growth and margins is seen as a critical test for the stock's near-term direction.
In uncertain markets, low-volatility stocks offer comfort but may cap upside potential. We analyze one steady performer and two stocks where stability may signal stagnation, helping investors balance risk and reward.
The benchmark index has been trapped in a tight range for months, gaining a mere 1% since October as a defensive rotation into energy and healthcare pressures tech-heavy portfolios. Analysts warn the prolonged consolidation is creating a 'ticking clock' scenario, setting the stage for a decisive breakout or breakdown.
Investor Kevin O'Leary delivers a blunt message to young entrepreneurs: glorifying overwork is not a badge of honor but a strategic liability. He advocates for sleep, nutrition, and exercise as the real drivers of founder optimization.
Thai troops now occupy a shell-damaged compound in O'Smach, Cambodia, which officials identify as a former hub for international scam operations. A military-led tour revealed a labyrinth of soundproofed call centers, fake police stations, and meticulous scripts, shedding light on a multi-billion dollar criminal enterprise.
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Phillip Securities initiates coverage of Palantir Technologies with a Buy rating, citing its AI software segment's robust growth and significant market expansion potential. A new partnership with Innodata aims to enhance Palantir's rodeo analysis platforms through advanced data services.
A newly surfaced 2014 email from the Jeffrey Epstein documents reveals Bitcoin-aligned executives warning investors about backing rival projects like Ripple. Some XRP proponents are framing the disclosure as validation of the token's early significance, though market momentum remains bearish.
While individual investors hold a significant 32% stake in Krona Public Real Estate AB (FRA:927), effective control rests with public companies, which command a 40% ownership bloc. This concentration of power raises questions about corporate governance and future strategy for the Swedish property firm.
The probate process can drain an estate's assets and burden heirs for years. Financial and legal experts outline practical steps families can take now to ensure a smoother transfer of wealth.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for safety. We analyze one steady performer with durable advantages and two companies where challenges may outweigh the stability premium.
With over half the early vote counted, governing party candidate Laura Fernandez appears poised to secure a first-round victory, potentially avoiding a runoff.
A federal judge has indicated she is likely to dismiss Elon Musk's xAI lawsuit accusing OpenAI of stealing trade secrets, dealing a significant blow to the tech billionaire's legal offensive against his former AI venture.
Recent buying activity by multiple executives at AdNeo Limited suggests internal optimism about the company's trajectory, even as its stock trades below their purchase price.
While the small-cap index is famed for its hidden gems, some constituents face headwinds that make them less compelling for growth-focused portfolios. Here's a look at three companies analysts are currently avoiding.
Market volatility presents both risk and opportunity. We analyze two fundamentally sound yet turbulent stocks that may reward the patient, and flag one whose wild swings are best left to speculators.
Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
